Australia's Clarity Pharmaceuticals jumps as cancer drug gets U.S. FDA nod
21/11/2022 24:11
** Shares of radio-pharmaceutical firm Clarity Pharmaceuticals
CU6.AX jump as much as 6.5% to A$0.985, on track for their
biggest pct gain since Nov. 9
** Co says it has received approval for SAR-Bombesin
product's investigational new drug application from the U.S.
Food and Drug Administration urn:newsml:reuters.com:*:nTUE83C633
** Says its SAR-Bombesin product will explore use for
identification and treatment of metastatic castrate-resistant
prostate cancer
** Shares hit highest since Nov. 15
** Stock up 25% this year as of last close, vs a 3.9%
decrease in the benchmark S&P/ASX 200 index .AXJO
(Reporting by Roushni Nair in Bengaluru)
((Roushni.Nair@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial